Investors: Press Releases

  • All
  • Non-Regulatory
  • Regulatory
Regulatory

Allarity Therapeutics Submits Premarket Approval Application to U.S. FDA for DRP® Companion Diagnostic for Dovitinib

Regulatory

Notice of Annual General Meeting

Regulatory

Allarity Therapeutics Publishes its Annual Report for 2020

Non-Regulatory

Allarity Therapeutics Invites Investors for FY/Q4 2020 Report Conference Call

Regulatory

Allarity Therapeutics plans fully guaranteed rights issue of approximately SEK 100 million

Regulatory

Allarity Therapeutics Announces Positive Data from Preclinical Study of Dovitinib in Osteosarcoma

Regulatory

Allarity Therapeutics Initiates Phase 2 Trial of IXEMPRA® in Europe for the Treatment of Metastatic Breast Cancer

Regulatory

Allarity Therapeutics Provides Update on Pre-Clinical Testing of Stenoparib’s Antiviral Activity Against New Variants of Coronavirus

Regulatory

Allarity Therapeutics Draws Down the Fourth Tranche Under Its Convertible Note Agreement with Negma Group LTD and Park Partners GP

Regulatory

Allarity Therapeutics to test activity of its PARP inhibitor, stenoparib, as a potential therapy for new highly infectious Strain B.1.1.7 of Coronavirus

Regulatory

Allarity Therapeutics issues new shares to Aalto Capital in connection with services rendered

Regulatory

Allarity Therapeutics Draws Down the Third Tranche Under Its Convertible Note Agreement with Negma Group LTD and Park Partners GP

Regulatory

2020 in Review: A Letter from Allarity’s CEO

Regulatory

Allarity Therapeutics Expands its Stenoparib License Rights to Include Anti-Viral Uses

Regulatory

Allarity Therapeutics Publishes Interim Report for the Period January – September 2020

Non-Regulatory

Allarity Therapeutics Invites Investors for Q3 2020 Report Conference Call

Regulatory

Allarity Therapeutics Draws Down the Second Tranche Under Its Convertible Note Agreement with Negma Group LTD and Park Partners GP

Regulatory

Allarity Therapeutics Hires New Chief Financial Officer

Regulatory

Allarity Therapeutics Gains Allowance from U.S. Patent and Trademark Office for New DRP® Biomarker Patents

Regulatory

Allarity Therapeutics Provides Update on Dovitinib Program

Sign up for press releases

Sign up for press releases and receive relevant information about Allarity Therapeutics A/S.